Analysts think AQST stock price could increase by 187%
Jan 12, 2026, 12:25 PM
-1.15%
What does AQST do
Aquestive Therapeutics, headquartered in Warren, New Jersey, develops differentiated pharmaceutical products for unmet medical needs, including severe allergic reactions and CNS diseases, using its proprietary PharmFilm technology. The company's portfolio includes Anaphylm and Libervant, with an IPO launched on July 25, 2018.
11 analysts think AQST stock price will increase by 187.32%. The current median analyst target is $11.22 compared to a current stock price of $3.90. The lowest analysts target is $8.08 and the highest analyst target is $15.75.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.